

# Neurotech

2 March 2021

## Neurotech Expands License with Dolce Cann Global

### Highlights

- **Exclusive license expanded from Autism, Epilepsy and ADHD to now include all neurological disorders.**
- **Solid scientific rationale for portfolio expansion based on the potent anti-inflammatory and neuro-modulatory activity of NTI/Dolce strains.**

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company") is pleased to announce the expansion of its exclusive license with Dolce Cann Global Pty Ltd to now include all neurological disorders, specifically - Autism, Epilepsy, ADHD, Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Transverse Myelitis, Inflammatory Brain disease, Fibromyalgia, Chronic Fatigue, Migraine and any other disorder, disease or affliction affecting the human brain function.

Latest clinical research demonstrates that inflammation, and more specifically neuroinflammation - is a well-recognised common feature in all neurological disorders<sup>1</sup>. Based on the scientific data generated to date, unlike CBD alone the NTI/Dolce full spectrum medicinal cannabis strains have powerful, neuro-modulatory, anti-inflammatory and neuro-regulatory mode of action. The activity of these strains is up to 80% more potent than CBD alone and can regulate the suppression of inflammation via the suppression of the Arginase 1 pathway and beta- tubulin regulation which is a vital protein in the management of several neurological diseases such as Alzheimer's disease, Huntington's disease and Multiple Sclerosis.

The global market for neurology treatments is expected to grow to \$39.4 billion by 2024<sup>2</sup>. Rising prevalence of neurological diseases coupled with increasing awareness associated with the disease diagnosis in developing countries is assisting the market growth.

Brian Leedman, Chairman of Neurotech International said, "The amendment of the Dolce Cann Global licence provides scope for the Company to expand our research programs beyond the current program with its focus on autism in children that is due to commence later this month".

### Deed of Variation Terms

In consideration for the licensors agreeing to vary the licence deed, the Company as licensee must issue 15,000,000 shares to Dolce Cann Global or its nominee within 45 business days after the date of the deed (1 March 2021), and a further 15,000,000 shares to Dolce Cann Global or its nominee within 45 business days after the Company successfully completes a small-scale clinical trial based on a neurological disorder (excluding Autism, Epilepsy or ADHD) within two years after the date of this deed.

The initial tranche of 15,000,000 shares will be issued under the Company's remaining placement pursuant

---

<sup>1</sup>The Role of Inflammation in Neurological Disorders  
Author(s): Diana Degan, Raffaele Ornello, Cindy Tiseo, Antonio Carolei, Simona Sacco, Francesca Pistoia\*  
Journal Name: Current Pharmaceutical Design

<sup>2</sup> [\\*\\*https://www.biospace.com/article/neurological-disorder](https://www.biospace.com/article/neurological-disorder)  
19 March 2020

to ASX Listing Rule 7.1. The Company intends to seek shareholder approval for the issue of the second tranche of 15,000,000 shares.

### **Authority**

This announcement has been authorised for release by the Board of the Company.

### **Further Information**

Brian Leedman  
Chairman  
bleedman@neurotechinternational.com  
+61 (0)41 228 1780

Winton Willesee  
Non-Executive Director  
winton@azc.com.au  
+61 (0)41 066 7844

### **About Neurotech**

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>

<http://www.mentetech.com>

---

#### **Neurotech International Ltd**

ABN 73 610 205 402  
Suite 5 CPC, 145 Stirling Highway  
Nedlands, Western Australia 6009  
[www.neurotechinternational.com](http://www.neurotechinternational.com)